Homotoxicology

1. Introduction

Version followed: homotoxicology as described by the manufacturer Heel (company history page) and by the Thieme textbook Introduction to Bioregulatory Medicine (Smit, O'Byrne, Van Brandt, Bianchi, Küstermann, 2009), which uses the newer label "bioregulatory medicine". The six-phase scheme is given as a German medical newspaper (Ärzte Zeitung, 2007) and a practitioner article (Demers, IVC Journal, 2014) set it out. Wording differs between these sources, and the differences are noted below. Sections 1–3 describe the method as its own makers and practitioners publish it. Section 4 covers only the psychotherapist's own work with a client who uses or is considering it. The psychotherapist never performs, sells, prescribes or recommends homotoxicology products or treatments.

What it is. Homotoxicology is a remedy system developed by the German physician and homeopath Hans-Heinrich Reckeweg (1905–1985) [source: Ärzte Zeitung 2007]. In 1936 he founded the company now called Heel; the name stands for "Herba est ex luce". The company was founded in Berlin, revived in Triberg in 1946 and moved to Baden-Baden in 1954 [source: Heel history page]. Heel dates the concept to 1948, while Ärzte Zeitung says Reckeweg formulated its basis around 1952 [uncertain: sources differ on the date]. The system uses mostly complex homeopathic preparations: fixed combinations of several ingredients, often at several potencies. Unlike classical homeopathy, these are chosen by diagnosis rather than by an individual remedy picture. For that reason its proponents call it a "bridge" between conventional medicine and classical homeopathy [source: Ärzte Zeitung 2007; Crislip 2014]. The products are called "antihomotoxic medicines", and the treatment "antihomotoxic therapy" [source: Thieme 2009 book description].

Core idea of how change happens, as the system holds it. The body is described as a flow system: substances flow in, are transformed and flow out. Disease is described as the body's response to "homotoxins", meaning any harmful substance from outside or inside the body, or as its attempt to compensate for damage those substances cause [source: Ärzte Zeitung 2007; Crislip 2014]. Treatment first aims to stop the toxin intake (the example given is giving up nicotine). It then gives low-dose "healing stimuli" chosen by phase, intended to support the body's self-regulation [source: Ärzte Zeitung 2007]. Change is described as movement backwards through the six phases, towards excretion and away from deeper, cellular stages. These are the system's own claims and are attributed to it, not stated as fact.

2. Framework

2a. The method's own framework, as published

The six phases (the "Disease Evolution Table" or six-phase table). Sources differ slightly in their labels:

Phase	Ärzte Zeitung 2007 (German)	Crislip 2014 / Demers 2014 (English)
1	Ausscheidung: elimination through sweat, urine, bile, stool	Excretion
2	Entzündung (inflammation)	Reaction / Inflammation
3	Beginning storage of toxins	Deposition: stored in connective tissue, vessels, fat
4	Final storage; cells become ill	Impregnation
5	Permanent damage (degeneration)	Degeneration
6	Malignant change	Neoplasm / Dedifferentiation

[source: Ärzte Zeitung 2007; Crislip 2014; Demers 2014]. Phase 6 is labelled cancer in the scheme. This guide does not present homotoxicology as a treatment for cancer or any other physical disease.

Biological divide. Proponents place a line between phase 3 (deposition) and phase 4 (impregnation). They describe the first three phases as easier to reverse, and the phases beyond the line as chronic disease with tissue damage [source: Demers 2014; Crislip 2014].
Vicariation. Movement between phases is called vicariation. It can go forwards (progressive, said to mean worsening) or backwards (regressive, said to mean healing) [source: Ärzte Zeitung 2007, which describes the two directions without using the adjectives; the terms progressive and regressive vicariation are standard in the literature but were not verified in the primary text: uncertain: not verified].
Three pillars of antihomotoxic therapy: drainage and detoxification, immunomodulation, and cell and organ support [source: Thieme 2009 description; Crislip 2014].
Preparation groups. The literature describes groups of preparations (plant, mineral, catalyst, organ). Practitioners link product groups to phases [source: Thieme 2009; Crislip 2014; Demers 2014]. Products, potencies and combinations are deliberately not listed here.

What a client experiences. A consultation with a doctor, naturopath, other practitioner or (for animals) a veterinarian who uses Heel-type complex remedies. This typically includes:

a phase assessment;
advice to reduce "toxin" exposure;
products in oral, topical or injectable form.

Injectable ampoules ("Injeel") have existed since 1959 [source: Heel history]. Some practitioners describe injections at acupuncture points and "autosanguis" procedures, in which the patient's own blood is used [source: Demers 2014, veterinary]. Clients may also be told that symptoms flaring or "moving outward" are signs of healing (regressive vicariation) [source: Ärzte Zeitung 2007; Demers 2014; the application to flare-ups is synthesis].

Who practises it. Physicians and homeopaths, mainly in German-speaking countries, Eastern and Central Europe and South America, as well as naturopathic and veterinary practitioners elsewhere [source: Heel press release quoted by Ernst 2014; Demers 2014]. Training is offered mainly through manufacturer symposia and courses. Heel symposia date from 1957 [source: Heel history]. No independent certification body was identified [uncertain: not verified].

Regulation and status (one line each)

United States: FDA regards all homeopathic drugs as new drugs that are unapproved unless FDA-approved. Its 2022 final guidance sets out risk-based enforcement priorities, and a 2025 federal court ruling upheld that FDA treats homeopathic products as new drugs subject to approval [source: FDA Law Blog 2022, 2025]. The FTC (2016) requires competent and reliable scientific evidence for health claims about OTC homeopathic products, or prominent disclosure that no scientific evidence shows they work [source: FTC 2016]. Heel announced in May 2014 that it would end US and Canadian business on 31 August 2014, citing the financial burden of class actions. Its US operations passed to MediNatura, and international brands such as Traumeel and Zeel were discontinued in the US [source: Ernst 2014 quoting Heel's press release; New Hope 2014].
United Kingdom: MHRA registers homeopathic products either under a simplified scheme (no therapeutic indications; oral or external use only, not injections) or under a National Rules Scheme (indications limited to minor conditions not needing a doctor's supervision) [source: GOV.UK MHRA guidance]. NHS England (2017) lists homeopathy among items not to be routinely prescribed, and NICE recommends it for no condition [source: SPS/NHS England 2017].
Germany: Heel is based in Baden-Baden. Statutory-insurance reimbursement of homeopathy was reported in 2026 as being removed [uncertain: not verified; news item only]. The licensing framework under German medicines law was not verified [uncertain: not verified].
Australia: the NHMRC (2015) found no health condition for which homeopathy was shown to be effective [source: SPS/NHS England 2017, summarising NHMRC].
Canada: Heel withdrew in 2014 [source: Ernst 2014]. The current Health Canada status of these products was not verified [uncertain: not verified].
Evidence status (one line): no reliable evidence of effectiveness for homeopathy for any condition (NHMRC 2015). A 2004 review of homotoxicology trials, cited secondarily, concluded that placebo-controlled trials did not demonstrate efficacy [source: SPS 2017; Crislip 2014; uncertain: review itself not verified].

2b. The psychotherapist's framework alongside it [synthesis]

This is not a separate course of therapy. It is woven into ongoing psychotherapy over these stages:

Ask and record (assessment and intake; revisit at reviews). Goal: know what the client uses, from whom and why. Move on once use is recorded and the client has said what it means to them.
Understand meaning and explanatory model (1–2 session segments). Goal: a shared map of the client's beliefs about toxins, phases and healing. Move on once the client feels understood and not judged.
Informed, values-based decision support (as decisions arise). Goal: the client decides freely, with accurate information about regulatory status and risks, and with their doctor in the loop. Move on once the decision is the client's, documented, and medical care is intact.
Coordination (with consent, at any point). Goal: the prescriber or pharmacist knows about the use.
Risk monitoring and review (every review; immediately on red flags). Goal: notice delayed care, risky reframing of worsening, harm to children or dependants, financial or group pressure. Step up to section 4 risk interventions when flags appear.

Format: individual sessions, with a family session where children or dependants are involved. Typical time: 10–20 minutes at intake, then brief check-ins [synthesis].

3. Guiding principles

All principles below are [synthesis] unless a source is shown.

Never perform, sell, prescribe or recommend. Do not name products, suggest a practitioner, or comment on remedy choice, potency or dosing. Route all remedy and medicine questions to the prescriber or pharmacist.
Curiosity before information. Ask what it means to the client before saying anything about evidence. Defensiveness closes the conversation and drives use underground.
Describe, attribute, do not ridicule. Speak of "homotoxins", "phases" and "drainage" as the system's ideas ("in homotoxicology, ..."). This lets the client feel accurately understood without being told you endorse or dismiss them.
Autonomy with accurate information. Adults may choose complementary products. Your job is to make the choice informed and free, not to make it for them [source for informed consent: APA Ethics Code 3.10, 10.01].
Keep medical care intact. The one non-negotiable aim is that the system's language never replaces assessment of new, worsening or serious symptoms by a doctor. Regulators warn against using homeopathy for chronic or serious conditions in place of effective treatment [source: NHMRC via SPS 2017].
Watch the "worsening means healing" frame. Regressive vicariation can turn deterioration into reassurance. Treat any worsening as a reason for medical review, whatever the frame.
Coordinate with consent. Work with the client's doctor or pharmacist when appropriate, sharing only what is needed and only with consent, except where law or safety requires otherwise [source: APA Ethics Code 3.09, 4.05].
No conflicts of interest. No referral fees, product sales, affiliate links or dual roles [source: APA Ethics Code 3.05, 3.06, 6.07].
Stay within competence. You are not the judge of pharmacology or diagnosis. Say so plainly and refer [source: APA Ethics Code 2.01].
Children and dependants come first. A parent's right to choose for themselves does not extend to withholding needed care from a child. Safeguarding duties apply.
Document neutrally. Record what the client uses, its meaning, any risk discussion, consent to coordinate, and decisions, in non-pejorative language.
Treat the psychology, not the remedy. Health anxiety, fear of contamination, somatic distress, distrust of medicine and grief are within your scope. Treat them with established methods (see Domain II).

4. Intervention inventory

These are the psychotherapist's own interventions alongside homotoxicology. None of them involves performing, selling, prescribing or recommending a remedy, injection or procedure. All steps and wording are [synthesis] unless a source is shown. Example therapist language is illustrative.

4.1 Routine, non-judgemental inquiry and recording

Purpose / when: at intake and at every formal review, for every client, not only those who seem "alternative". Use of complex homeopathic products is easily missed because clients may call them "natural drops", "injections from my doctor" or brand names, and may not think of them as medicine.
Steps:
1. Normalise: say that you ask everyone about all the things they use for their health.
2. Ask open questions about products, injections, practitioners, and any "detox" or "drainage" programme.
3. Ask who advised it (doctor, naturopath, pharmacist, friend, online seller) and whether their GP or prescriber knows.
4. Ask about cost and how it is paid for.
5. Record: what (as the client names it), route (oral, topical, injected), source, start date, the doctor's awareness, cost, and the client's stated purpose. Use neutral language ("uses homotoxicology complex remedies from a naturopath"), not judgement.
Example language (illustrative): "I ask everyone about anything they use for their health: prescribed, bought, or given by another practitioner, including drops, tablets or injections. What are you using at the moment?" / "Does your GP know about these? You're not in trouble either way; I just want to know who has the full picture."
Watch for: brief or guarded answers (fear of disapproval); injections given outside a medical setting; use started for a serious or progressive condition; large or rising spending. Working if: the client volunteers updates at later sessions without prompting.

4.2 Mapping the client's explanatory model

Purpose / when: once use is known, to understand how the client thinks illness and healing work, in the system's own terms.
Steps:
1. Ask the client to explain the approach as they understand it. Let them use their own words: toxins, "homotoxins", phases, drainage, "the biological divide", symptoms "coming out".
2. Reflect it back accurately, attributed ("so in this approach, ...").
3. Ask where their current symptoms sit in that model and what the practitioner said would happen next.
4. Ask specifically what they were told it means if symptoms get worse. This tells you whether a "worsening means healing" frame is in play (see 4.7).
5. Note which beliefs are flexible ("it might help") and which are fixed ("medicine drives toxins deeper").
Example language (illustrative): "Help me understand this approach the way your practitioner explained it. What do they think is going on in your body?" / "In homotoxicology, as you describe it, the body is trying to push toxins out. What did they say a flare-up would mean?"
Watch for: beliefs that conventional medicines "suppress" illness and push it deeper (a view some practitioners publish [source: Demers 2014]); fear of contamination; a model that makes any worsening reassuring. Working if: the client says you understand how they see it, and can say how sure they are of each part.

4.3 Exploring meaning, hopes, expectations and what draws the client

Purpose / when: after 4.2, or when use seems emotionally charged, expensive or escalating. Use often meets needs that matter clinically: control, hope, being taken seriously, distrust of medicine after bad experiences, identity, family tradition, or belonging to a community.
Steps:
1. Ask what drew them and what it gives them that other care has not.
2. Explore hopes: what would "working" look like, and by when?
3. Explore past medical experiences, especially feeling dismissed, harmed or rushed.
4. Name the need underneath (control, being heard, hope) and validate it separately from the remedy.
5. Consider whether the same need can also be met in other ways: a better-fitting doctor, a second opinion, self-management skills, or peer support.
Example language (illustrative): "What does this approach give you that you haven't found elsewhere?" / "It sounds like the practitioner really took time with you, and that mattered after feeling brushed off." / "If this were working, what would you notice first?"
Watch for: hope pinned entirely on the remedy for a serious condition; grievance with medicine that blocks all contact with doctors; identity so tied to the approach that questions feel like attacks. Working if: the client talks about needs and values, not just products, and is more open about the medical side.

4.4 Sharing accurate, attributed information (only when invited or when risk requires)

Purpose / when: when the client asks your view, or when a decision with health consequences is being made. You give regulatory and evidence status as regulators state it, without debating the theory and without advising on products.
Steps:
1. Ask permission first.
2. Give the regulator-level facts briefly:
  - in the US, homeopathic products are treated as unapproved drugs, and advertising of OTC homeopathic products must have scientific evidence or disclose that there is none [source: FDA Law Blog 2022; FTC 2016];
  - in the UK, registered homeopathic products either carry no indications or are limited to minor conditions [source: GOV.UK MHRA];
  - Australia's NHMRC found no condition for which homeopathy was shown effective [source: SPS 2017].
3. Separate facts from your role: you are not the person to judge any specific product, and their doctor or pharmacist is.
4. Ask what they make of it, and let the client respond without pressure.
Example language (illustrative): "Would it help if I told you what the regulators say, and then you decide what to do with that?" / "I can't judge any particular remedy; that's for your doctor or pharmacist. What I can tell you is how these products are regulated."
Watch for: information delivered as a lecture; client shame or withdrawal; you drifting into product commentary. Working if: the client can repeat the facts in their own words and still feels free to choose.

4.5 Supporting an informed, values-based decision

Purpose / when: when the client is choosing whether to start, continue, add to or replace other care, especially for a significant condition. No published decision aid specific to homotoxicology was identified [uncertain: not verified], so the structure below is general [synthesis].
Steps:
1. Clarify the decision in one sentence (e.g. "use these alongside my prescribed treatment" versus "instead of it").
2. Elicit values: what matters most (safety, feeling in control, natural approaches, cost, family views).
3. List the options, including "both, with my doctor informed" and "try, with a review date and agreed warning signs".
4. For each option, ask what the client knows about benefits and risks, and who could tell them more (doctor, pharmacist).
5. Check that the decision is free: no pressure from a practitioner, seller, partner or group.
6. Agree a review point and personal warning signs that would prompt a medical visit.
7. Document the decision as the client's.
Example language (illustrative): "Let's be clear on exactly what you're deciding." / "What matters most to you here?" / "If you go ahead, what would tell you it's time to see your doctor, whatever the remedy suggests?"
Watch for: decisions to stop or delay prescribed treatment, or to avoid diagnosis; deadlines set by a seller; decisions driven by shame. Working if: the client can state their reasons, the alternatives and their warning signs, and medical care stays in place.

4.6 Coordinating with the client's doctor or pharmacist

Purpose / when: when the client takes prescribed medicines, has a significant condition, receives injections, is pregnant, or is the parent of a child using products [source for cooperation and consented disclosure: APA Ethics Code 3.09, 4.05].
Steps:
1. Explain why coordination helps (one complete picture, safety) and ask for consent.
2. Agree what will be shared and how: the client tells the doctor, you write, or a joint letter.
3. Encourage the client to bring product names or packaging to the prescriber or pharmacist.
4. Share only what is needed: what is used, and any concern (e.g. a delayed investigation).
5. Record the consent, what was shared and any reply.
6. Never relay advice about starting, stopping or changing any medicine or remedy. Direct the client to the prescriber.
Example language (illustrative): "Would you be OK with your GP knowing about these? Pharmacists can check products against your other medicines; that isn't my area." / "I won't tell you to stop or start anything. That conversation belongs with your doctor."
Watch for: refusal grounded in fear of being scolded (address that fear first); the client stopping a medicine on a practitioner's advice. Working if: the doctor knows, and the client reports a respectful exchange.

4.7 Working with the "worsening means healing" frame (regressive vicariation, "drainage")

Purpose / when: when a client reports new or worse symptoms and explains them as toxins "coming out", a reaction to drainage, or movement back through the phases. The system describes movement between phases in both directions [source: Ärzte Zeitung 2007]; reading a particular flare as healing is a risk point [synthesis].
Steps:
1. Acknowledge the client's interpretation without arguing about it.
2. Separate two questions: "what does it mean in your approach?" and "has a doctor looked at it?"
3. Agree that new, severe, persistent or unexplained symptoms get medical assessment, whatever the explanation.
4. Agree concrete warning signs in advance (e.g. high fever, breathing difficulty, bleeding, rapid weight loss, signs of infection at an injection site, symptoms in a child), and what the client will do if they occur.
5. Follow up at the next session.
Example language (illustrative): "Your practitioner sees this as the body clearing something out. That may be how the approach explains it. And it's also exactly the kind of change a doctor should look at, so you can be sure nothing else is going on." / "Can we agree now what would make you see a doctor straight away?"
Watch for: repeated reframing of deterioration as progress; reluctance to be examined because it "interrupts the process"; phase-6 (cancer) language used about a lump or symptom that has not been investigated. Working if: the client gets symptoms checked and can hold both frames at once.

4.8 Recognising and responding to risk

Purpose / when: throughout, and immediately when a flag appears. Respond step by step, from exploring, through urging medical contact, to safeguarding or reporting.
Risk flags and responses:
- Stopping or delaying medical care, or avoiding diagnosis. Regulators warn against using homeopathy in place of effective treatment for chronic or serious conditions [source: NHMRC via SPS 2017]. Response: use 4.5 and 4.7, urge prompt medical review, and with consent involve the doctor (4.6). If the client has capacity and declines, respect their choice, document it and keep the door open.
- Injections or blood-based procedures. The product range includes injectables, and some practitioners describe injections at acupuncture points and autosanguis procedures [source: Heel history; Demers 2014]. UK simplified registration excludes injectable forms [source: GOV.UK MHRA]. Response: ask who gives them and in what setting, encourage the client to tell their doctor, and act on any signs of infection or injury as a medical matter. Do not comment on the procedure itself.
- Children. Parents may use these products for their children. Response: explore without blame. If a child's needed care, assessment or treatment is being withheld or delayed, follow your safeguarding procedures (4.12).
- Pregnancy. Response: encourage the client to tell their midwife, obstetrician or pharmacist about all products. Do not advise on any product.
- Eating disorders and "detox" or "drainage" language. Toxin and cleansing narratives can fit with restriction, purging or orthorexic patterns [synthesis]. Response: screen for disordered eating when detox or drainage regimes come up. If indicated, refer for medical assessment and eating-disorder-specialist care.
- Financial exploitation. Watch for costly multi-product regimes, open-ended courses, or practitioners who also sell the products. Response: explore spending and feelings about it, and support the client to ask for itemised costs and to say no.
- Group or practitioner pressure. Watch for urgency, threats that stopping will "drive disease deeper", discouraging contact with doctors, or isolation from sceptical family. Response: name the pressure and support autonomy. Consider high-control-group frameworks if the pattern is broader.
- Suicide or self-harm risk arising from despair after failed treatments: follow standard risk assessment.
Example language (illustrative): "I've noticed the appointments with your doctor have stopped since this started. Can we talk about that?" / "When someone says stopping will push illness deeper, that can make it really hard to feel free to choose. How does that sit with you?"
Watch for: your own urge to argue, which tends to harden positions. Working if: risks are named, medical care is restored or knowingly declined by a capable adult, and children are protected.

4.9 Health anxiety, somatic symptom presentations and toxin fears

Purpose / when: when use is driven by persistent worry about illness, bodily sensations read as toxin overload, or symptoms attributed to environmental exposures (idiopathic environmental intolerance). Treat the psychological problem with established approaches; see Domain II for full protocols.
Steps:
1. Assess the pattern: frequency of body checking, reassurance seeking (including repeat practitioner visits and product buying), avoidance, and impairment.
2. Make a shared formulation: how worry, attention to the body, checking and reassurance (including new remedies) keep the cycle going.
3. Use CBT for health anxiety or somatic symptom disorder components (see Domain II): psychoeducation on attention and sensation, reducing checking and reassurance, behavioural experiments, and graded return to avoided activities.
4. For toxin or contamination fears, explore the beliefs collaboratively. Do not argue biology; test predictions.
5. Keep one regular medical contact for real symptoms, so the client neither over-investigates nor neglects them.
Example language (illustrative): "Each new remedy seems to bring relief for a while, then the worry returns. Shall we map that cycle together?" / "What do you predict would happen if you went a week without checking for signs of toxins?"
Watch for: remedy switching as a safety behaviour; real medical symptoms being dismissed as "anxiety". Working if: checking and reassurance-seeking fall, functioning improves, and medical contact becomes appropriate rather than excessive or absent.

4.10 Managing your own stance and conflicts of interest

Purpose / when: always, and especially if you have personal views about complementary medicine, or links to practitioners or sellers.
Steps:
1. Do not sell, distribute, refer for payment to, or promote products or practitioners [source: APA Ethics Code 3.06, 6.07].
2. Avoid dual roles with practitioners the client uses [source: APA Ethics Code 3.05].
3. Notice countertransference (scorn or enthusiasm) and take it to supervision.
4. If the client asks you to endorse a practitioner or product, decline warmly and redirect to their doctor or pharmacist.
Example language (illustrative): "I don't recommend products or practitioners either way. It's not my field, and I want you to trust that my view isn't coloured by anything."
Watch for: subtle steering through tone or selective curiosity. Working if: the client experiences you as neutral and safe to tell.

4.11 Reporting routes

Purpose / when: when a client experiences an adverse reaction, misleading health claims, unsafe practice, or exploitation, or when a child is at risk.
Steps:
1. Help the client decide whether to report, and support them to do it themselves where possible.
2. Choose the route:
  - Product adverse effects: the national medicines regulator (UK MHRA Yellow Card; US FDA MedWatch) [uncertain: not verified].
  - Misleading advertising: in the US, the FTC enforces substantiation for homeopathic claims [source: FTC 2016]; in the UK, the Advertising Standards Authority or Trading Standards [uncertain: not verified].
  - Unsafe or exploitative practice by a regulated professional: that professional's licensing board.
  - Children: local safeguarding or child-protection services.
3. Keep confidentiality within the law; disclose without consent only where law or safety requires [source: APA Ethics Code 4.05].
4. Document what was reported, to whom, and why.
Example language (illustrative): "What happened after the injection sounds like something the medicines regulator would want to know about. Would you like help reporting it?"
Watch for: the client's fear of getting a trusted practitioner into trouble. Working if: the client feels supported, not pushed.

4.12 Children, families, consent and assent

Purpose / when: when products are used for a child, or a family is in conflict over them.
Steps:
1. Explore the parent's reasons with the same respect as for an adult (4.2–4.3).
2. Check that the child is under ordinary medical care and that the doctor knows about the products (4.6).
3. Seek age-appropriate assent and hear the child's view in their own words.
4. If a child is deprived of needed medical care or assessment, or given harmful procedures, follow your safeguarding procedure and local law.
5. In family conflict, help the adults focus on the child's safety and shared values, not on winning the argument.
Example language (illustrative): "You both want what's best for her. Can we start from what you agree on: that her doctor keeps seeing her?"
Watch for: a child's symptoms reframed as "healing" and left unassessed. Working if: the child's medical care is intact and parents can discuss choices without escalation.

4.13 Documentation and review

Purpose / when: at every contact where use, risk or decisions are discussed.
Steps: record use, meaning, the information given, decisions and who made them, consent to coordinate, risk flags and actions, and the next review date. Revisit at formal reviews and whenever health status changes.
Example language (illustrative): "I'll note that you've decided to continue alongside your medical treatment, and that we'll check in about it next month. Does that sound right?"
Watch for: records that judge, or that are silent on risk discussions. Working if: another clinician could understand the situation and the client's choices from the notes.

5. Handling problems

The sources describe homotoxicology itself, not psychotherapy alongside it. All guidance in this section is [synthesis] unless a source is shown.

Client won't disclose, or minimises use. Usually fear of judgement. Response: repeat the normalising question at reviews, show neutrality in how you respond to the first small disclosure, and avoid evidence talk until trust exists.
Client asks "Do you think it works?" Response: say that it isn't your field to judge products, offer regulator-level facts if they want them (4.4), and turn back to what they hope for and how they'll know. Don't give a personal verdict either way.
Client asks you to recommend a practitioner, product or "phase" assessment. Response: decline warmly, explain your role, and direct them to their doctor or pharmacist (4.10).
Rupture: client feels judged after information-sharing. Response: name it, take responsibility for the impact, re-affirm their autonomy, and return to their goals. Ask permission before sharing anything further.
Entrenched distrust of medicine ("drugs suppress disease and drive it deeper"). Some practitioners publish this view [source: Demers 2014]. Response: explore the experiences behind the distrust, validate past harms, and look for one acceptable medical contact (a different GP, a pharmacist, a second opinion). Aim for contact, not conversion.
Symptoms worsening and framed as healing (regressive vicariation, "drainage reaction"). Response: use 4.7. Hold the line that worsening gets a medical look. If there is acute danger, follow urgent-care and emergency procedures.
Serious or progressive illness, including cancer, managed only with these products. Response: respectful conversation about hopes and fears, decision support (4.5), and with consent contact with the treating team. Support palliative-care referral where relevant. Later, help with grief and regret without blame. Regulators advise against using homeopathy instead of effective treatment for serious conditions [source: NHMRC via SPS 2017].
Non-adherence to prescribed medicine in favour of remedies. Response: explore reasons, never advise on the medicine, and with consent alert the prescriber. Support the client to discuss it with the prescriber themselves.
Overwhelm from conflicting advice (doctor versus practitioner, family versus client). Response: slow down, map who says what, return to the client's values, and break decisions into small, reversible steps with review dates.
Family conflict. Response: meet jointly if useful, reframe around shared aims (safety, the client's autonomy, the child's welfare), and agree how disagreements will be handled.
Financial strain or pressure to buy. Response: explore spending openly and support the client to set limits and ask for itemised costs. Consider consumer-protection routes if claims or sales practices seem misleading (4.11).
Health anxiety cycle maintained by remedy switching. Response: formulate, then use CBT for health anxiety (4.9; Domain II). Treat new remedies as possible safety behaviours, collaboratively and not as a ban.
Child at risk. Response: safeguarding takes priority over the therapeutic alliance. Explain your duty to the parent where it is safe to do so, and follow procedure (4.12).
Your own frustration or contempt. Response: supervision. Check your notes and language for judgement.
Market changes confuse the client (e.g. a familiar brand no longer sold, or a replacement product). Heel left the US and Canadian markets in 2014, and its US line was replaced by another company's products [source: Ernst 2014; New Hope 2014]. Response: route product questions to the pharmacist, and explore any distress about losing a trusted product.

Sources

Web sources:

Books cited:

Smit A, O'Byrne A, Van Brandt B, Bianchi I, Küstermann K (2009). Introduction to Bioregulatory Medicine. Thieme. Only the publisher's description was consulted; the book text itself is [uncertain: not verified].
Reckeweg's own writings (e.g. Materia Medica Homoeopathia Antihomotoxica) were not consulted [uncertain: not verified].

← Previous · XII-063Isopathy and nosodes Next · XII-066 →Schuessler cell salts